Follow Us in the News

Have you followed us in the news lately? We have had articles written about the Institute and about the Creighton Model System and NaProTechnology recently featured in the Chicago Tribune, Legatus Magazine, and Columbia Magazine!

Also, the NaPro approach to diagnosing and treating infertility will be the topic of discussion on the upcoming August 10th broadcast of Catholic Answers!

Follow the Pope Paul VI Institute and the Creighton Model System and NaProTechnology in the news at www.popepaulvi.com/inthenews.htm!

2011 AAFCP Annual Meeting

This summer, I will be presenting at the 2011 American Academy of FertilityCare Professionals Annual Meeting, which will be held in Duluth, Minnesota from July 20th through the 23rd. I will be speaking on Thursday morning, the 21st of July, on The Fetal Safety of Progesterone in Pregnancy. During my talk, I will be presenting the largest database in the world on the use of progesterone in pregnancy. I will detail fetal anomalies and will then compare the use of progesterone support with non-use. And, I will review the medical literature available on this topic.

I will also be available for two Q&A break-out sessions. The first one on Friday will be for medical professionals and will explore issues about NaProTechnology. The second session on Saturday will be for all attendees and will consider the application of the Creighton Model System and NaProTechnology and will explore practical uses of these in case-related areas.

I hope you can incorporate this meeting in your summer plans. For more information and to register, visit http://www.aafcp.org and click on “Annual Meeting” under the Events tab.

Record Numbers Complete Training

Record Number of Practitioners Complete Pope Paul VI Institute’s Training

For Immediate Release — April 11, 2011 (Contact: Sue Hilgers, Institute Advancement, (402) 505-8949, suehilg@aol.com)

(Omaha, Nebr.) From April 2-9, 2011, 107 women’s health practitioners from the U.S., Poland, Mexico, Nigeria, Ireland, New Zealand and Canada, gathered in Omaha to complete Education Phase II of the Pope Paul VI Institute for the Study of Human Reproduction’s training in the Creighton Model FertilityCare System and NaProTechnology. It is the largest number of practitioners to attend the Institute’s the annual training, which has been offered for 33 consecutive years.

The Pope Paul VI Institute for the Study of Human Reproduction is the leading education and research center in the United States in the area of natural regulation of human fertility and the development of morally and professionally acceptable reproductive health services. Dedicated to Pope Paul VI’s challenge to “physicians and health care professionals” and to “men of science,” it is a living memorial to the challenges placed before us by the Pope Paul VI in his encyclical letter Humanae Vitae (Of Human Life).

Each year, the Pope Paul VI Institute offers two Education Phases for national and international students in the following programs: Practitioner Interns, Medical Consultants, Double Program Interns (Practitioners and Medical Consultants), Nurse Practitioners, Physicians Assistants, and Pharmacists.


Medical practitioners from around the world pose with Dr. Hilgers (back row, tan jacket)
at the Pope Paul VI Institute Education Phase II training conference in Omaha, April 2-9.

According to patient and conference attendee Joanna Najfeld of Warsaw, Poland, the Creighton Model and NaProTechnology is a revolution in women’s health.

“I strongly believe that all women deserve the empowerment that comes from self-awareness of their body, navigating their own fertility in an educated and reliable manner,” she stated. “I am going to work with couples and women, teaching them to track the symptoms of their cycles in order to navigate fertility and monitor health, and, if necessary, obtain the proper NaProTechnology diagnosis and effective treatment for infertility, miscarriages, premenstrual syndrome, post partum depression, ovarian cysts, abnormal bleeding, or whatever the problem may be. I am really looking forward to making this revolutionary FertilityCare service accessible to women in my country.”

Another attendee, Ezenkwele Ezi, an OB/GYN practicing in Enugu, Nigeria, plans to return to her country and become a medical consultant of NaProTechnology. Dr. Ezenkwele said the most striking thing she learned in the second education phase is the possible link between NaProTechnology and breast cancer.

“More research needs to be done in this area,” she explained, “but the results could possibly provide a solution to preventing the breast cancer, which would be an enormous achievement in medicine.”

Dr. Lewis D. Lipscomb, an OB/GYN practicing in Winston-Salem, NC, said that after attending Education Phase I in October, 2010, he decided to cease prescribing contraception and performing sterilization.

“I can finally go to work with a true sense of peace, knowing that I am practicing in accord with my faith, and helping to promote a culture of life, family values, and respect of sexuality,” he stated.

The Creighton Model FertilityCare System and the new women’s health science of NaProTechnology have been developed through a research and education effort coordinated and directed by Thomas W. Hilgers, MD, director of the Omaha-based Pope Paul VI Institute for the Study of Human Reproduction and clinical professor in the Department of Obstetrics and Gynecology, Creighton University Medical Center.

The Creighton Model FertilityCare System provides comprehensive, professional services through individualized follow-up, standardized teaching tools and ongoing research. The Creighton Model is a medically standardized modification of the Billings Ovulation method. It is the only education program in this field that meets the education demands of a newly emerging allied health profession and provides a case management approach to teaching.

Two organizations unite Creighton Model FertilityCare Centers nationally and internationally: FertilityCare Centers of America and FertilityCare Centers International.

A highlight of the training conference was the presentation of a “Fides Et Ratio” (Faith and Reason) medal awarded to Dr. Thomas Hilgers by the Polish Catholic Scholar’s Guild. Pharmacist and Pope Paul VI Institute faculty member, Janina Filipczuk of Toronto, Canada, received the medal for Dr. Hilgers in Poland on March 19. She presented it to Dr. Hilgers, “for his faithful service of the human person and its dignity, as well as the affirmation of human fertility.”

***
Founded in 1985, the Pope Paul VI Institute for the Study of Human Reproduction has developed a new approach to women’s health care that embodies the best principles of medicine and offers superior treatments to women and challenges mainstream medicine, which relies on contraception, in vitro fertilization, and abortion. Through the Creighton Model FertilityCare System and NaProTechnology, its healthy, moral solutions to issues in women’s health care impact the lives of thousands of women, couples, doctors, medical students, priests, and babies nationally and internationally. More than 1,000 teachers and 300 physicians have been trained in the Creighton Model System.

Thomas W. Hilgers, MD
Senior Medical Consultant
Obstetrics, Gynecology, Reproductive Medicine and Surgery
Director: Pope Paul VI Institute for the Study of Human Reproduction
Clinical Professor Department of Obstetrics and Gynecology
Creighton University School of Medicine

Upcoming speaking engagement at the AAFCP Annual Meeting

Hilgers_2010

The American Academy of FertilityCare Professionals meets once a year to discuss timely issues relating to women’s health and FertilityCareTM. The organization was “founded in 1981 to foster, advance, and promote the Creighton Model FertilityCareTM System through service, education, leadership, and research.”

This year, the Academy is meeting in Greenville, South Carolina from July 21st to July 24th. The theme of the annual meeting will be Life, Liberty and the Pursuit of Truth. Here, I will be giving a talk entitled “Adrenal Fatigue; FP Progesterone Level Research Results; and Application to NaProTECHNOLOGY.”

For more information on the annual meeting of the American Academy of FertilityCare Professionals and to download a conference brochure, please visit http://www.aafcp.org/meeting_am.htm.

PCOD …Successful Surgical NaProTechnology

A number of women reading this right now might have polycystic ovaries. Polycystic ovaries are present in about 14 percent of otherwise healthy women and full-blown polycystic ovarian disease, or PCOD, afflicts approximately 6 percent of women. While many women who have PCOD do not exhibit any of the common symptoms, frequent indicators of PCOD may include amenorrhea (which is the absence of a menstrual period), obesity, facial hair (also called hirsuitism), and high blood pressure. PCOD is also associated with infertility. Women who have PCOD have ovaries that function abnormally and have irregular ovulation. Having polycystic ovaries puts women at risk for infertility, abnormal cholesterol levels, diabetes, high blood pressure, cardiovascular disease, thrombosis, and cancers including endometrial, ovarian and breast cancers. Women with PCOD also frequently have the signs of increased androgen levels, which are the male hormones in women. A physician can suspect PCOD if a woman exhibits these signs, which include facial hair, acne, and male-pattern baldness. PCOD puts women at risk for such things as infertility, cardiovascular disease, diabetes and even cancer. Yet, most women with PCOD receive inadequate treatment.

Therefore, all women with polycystic ovaries should be properly evaluated and treated. NaProTechnology aids women and physicians in identifying and treating polycystic ovarian disease, or PCOD. It uses a woman’s Creighton Model charts, which record various biological markers of her fertility and menstrual cycles. This information telegraphs abnormalities, such as long and irregular menstrual cycles which all women with PCOD have. NaProTechnology uses women’s Creighton model charts as the key for identifying and diagnosing PCOD. NaProTechnology treatment protocol seeks to establish normal hormone levels by using surgery to reduce the size of the ovary. NaProTechnology combines this surgery, called an ovarian wedge resection, with techniques that prevent scar tissue (called pelvic adhesions) and with hormone management.